Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 1;315(5):H1322-H1331.
doi: 10.1152/ajpheart.00136.2018. Epub 2018 Aug 24.

Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension

Thenappan Thenappan  1 , Stephen Y Chan  2   3 , E Kenneth Weir  1
Affiliations
Review

Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension

Thenappan Thenappan et al. Am J Physiol Heart Circ Physiol. .

Abstract

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the extracellular matrix (ECM) of the pulmonary arteries with increased collagen deposition, cross-linkage of collagen, and breakdown of elastic laminae. Extracellular matrix remodeling occurs due to an imbalance in the proteolytic enzymes, such as matrix metalloproteinases, elastases, and lysyl oxidases, and tissue inhibitor of matrix metalloproteinases, which, in turn, results from endothelial cell dysfunction, endothelial-to-mesenchymal transition, and inflammation. ECM remodeling and pulmonary vascular stiffness occur early in the disease process, before the onset of the increase in the intimal and medial thickness and pulmonary artery pressure, suggesting that the ECM is a cause rather than a consequence of distal pulmonary vascular remodeling. ECM remodeling and increased pulmonary arterial stiffness promote proliferation of pulmonary vascular cells (endothelial cells, smooth muscle cells, and adventitial fibroblasts) through mechanoactivation of various signaling pathways, including transcriptional cofactors YAP/TAZ, transforming growth factor-β, transient receptor potential channels, Toll-like receptor, and NF-κB. Inhibition of ECM remodeling and mechanotransduction prevents and reverses experimental pulmonary hypertension. These data support a central role for ECM remodeling in the pathogenesis of the PAH, making it an attractive novel therapeutic target.

Keywords: collagen; compliance; mechanotransduction; right ventricle; stiffness.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Pathogenesis of pulmonary vascular extracellular matrix (ECM) remodeling in pulmonary arterial hypertension (PAH). Increased shear stress from increased flow, hypoxia, inflammation, and altered bone morphogenic protein receptor 2 (BMPR2) signaling causes the endothelial-to-mesenchymal transition (EndoMT), in which endothelial cells acquire a mesenchymal phenotype with increased expression of a gene profile similar to smooth muscle cells. These myofibroblast-like cells cause remodeling of the ECM by increased deposition and cross-linkage of collagen through increased secretion of matrix metalloproteinases (MMPs), metalloproteases [a disintegrin and metalloproteinases (ADAMs)], serine elastases, and lysyl oxidases (LOXs), and decreased secretion of their endogenous inhibitors, like tissue inhibitors of metalloproteinase (TIMPs). HMGA1, high-mobility group AT-hook 1; IRF-1, interferon regulatory factor-1; PAECs, pulmonary artery endothelial cells; ROS, reactive oxygen species; TGF, transforming growth factor.
Fig. 2.
Fig. 2.
Pulmonary vascular extracellular matrix (ECM) stiffness induces pulmonary vascular remodeling. Stiff ECM activates yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling in pulmonary artery endothelial cells (PAECs), pulmonary artery smooth muscle cells (PASMCs), and pulmonary adventitial fibroblasts (PAFs) through mechanotransduction. Activation of YAP/TAZ signaling causes increased proliferation of PAECs and PASMCs through three different mechanisms: increased glutaminolysis and anaplerosis, upregulation of microRNA-21/27, and increased secretion of IL-6, endothelin, and fibroblast growth factor (FGF). In addition, stiff ECM increases PAEC proliferation by activating transforming growth factor (TGF)-β signaling, transient receptor potential channels (TRPCs), and Toll-like receptors (TLRs) as well as the NF-κB signaling axis through mechanotransduction. Finally, activation of YAP/TAZ signaling, in turn, leads to increased deposition of ECM by PAECs, PASMCs, and PAFs by upregulation of microRNA-130/301, leading to a feedback loop of increased ECM stiffness and mechanotransduction. ApoE, apolipoprotein E; CSA, cross-sectional area; LOX, lysyl oxidase; LRP8, LDL receptor-related protein 8; PAH, pulmonary arterial hypertension; PPARγ, peroxisome proliferator-activated receptor-γ; PVR, pulmonary vascular resistance.
Fig. 3.
Fig. 3.
Schematic illustration of the major steps in the development from pulmonary arterial collagen deposition to pulmonary arterial narrowing and potential therapeutic targets for treatment of pulmonary arterial hypertension (PAH). Increased shear stress, increased pulsatility, hypoxia, inflammation, and altered bone morphogenic protein receptor 2 (BMPR2) signaling cause the endothelial-to-mesenchymal transition (EndoMT), which, in turn, leads to remodeling of the extracellular matrix (ECM) and increased vascular stiffness through increased deposition and cross-linkage of collagen and breakdown of elastin. Increased stiffness promotes pulmonary endothelial cell, smooth muscle cell, and fibroblast cell proliferation. This causes pulmonary arterial remodeling with decreased compliance and cross-sectional luminal area leading to elevated pulmonary artery pressure and pulmonary vascular resistance. Potential novel therapeutic targets to treat PAH are presented in red boxes.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anand V, Roy SS, Archer SL, Weir EK, Garg SK, Duval S, Thenappan T. Trends and outcomes of pulmonary arterial hypertension-related hospitalizations in the United States: analysis of the nationwide inpatient sample database from 2001 through 2012. JAMA Cardiol 1: 1021–1029, 2016. doi:10.1001/jamacardio.2016.3591. - DOI - PubMed
    1. Anwar A, Li M, Frid MG, Kumar B, Gerasimovskaya EV, Riddle SR, McKeon BA, Thukaram R, Meyrick BO, Fini MA, Stenmark KR. Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 303: L1–L11, 2012. doi:10.1152/ajplung.00050.2012. - DOI - PMC - PubMed
    1. Archer SL. Pyruvate kinase and Warburg metabolism in pulmonary arterial hypertension: uncoupled glycolysis and the cancer-like phenotype of pulmonary arterial hypertension. Circulation 136: 2486–2490, 2017. doi:10.1161/CIRCULATIONAHA.117.031655. - DOI - PMC - PubMed
    1. Bellaye PS, Shimbori C, Upagupta C, Sato S, Shi W, Gauldie J, Ask K, Kolb M. Lysyl oxidase-like 1 protein deficiency protects mice from AdTGF-β1-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 58: 461–470, 2018. doi:10.1165/rcmb.2017-0252OC. - DOI - PubMed
    1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122: 164–172, 2010. doi:10.1161/CIRCULATIONAHA.109.898122. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources